文献速递心脑血管急症创伤与烧伤

S100B蛋白水平用于检测轻度创伤性脑损伤患者临床显著颅内出血:一项前瞻性队列研究的亚组分析

S100B protein level for the detection of clinically significant intracranial haemorrhage in patients with mild traumatic brain injury: a subanalysis of a prospective cohort study.
PubMed 文献 · Emerg Med J · 2020-12-18
一句话结论在轻度创伤性脑损伤非住院患者中,血浆S100B蛋白水平与临床显著颅内损伤无关,单独检测敏感性仅16.7%,不能用于减少头部CT。

本研究为前瞻性多中心队列研究的二次分析,纳入2013至2016年加拿大5家急诊科476例GCS 13-15分、伤后24小时内采血的非住院mTBI患者。24例(5.0%)存在临床显著颅内出血。S100B在中位数上两组相近(0.043 µg/L vs 0.039 µg/L),单独检测临床显著脑损伤的敏感性仅16.7%(95%CI 4.7%-37.4%),特异性88.5%(95%CI 85.2%-91.3%)。结论认为S100B与mTBI临床显著颅内病变无关,不支持用于减少CT检查。

要点

  • 在mTBI非住院患者中,S100B单独检测临床显著颅内出血的敏感性仅16.7%(95%CI 4.7%-37.4%),漏诊风险高。
  • S100B在有无临床显著脑损伤患者中的中位值相近:0.043 µg/L vs 0.039 µg/L,未显示关联。
  • 本队列临床显著颅内出血发生率为5.0%(24/476),非临床显著脑损伤为2.7%(13/476)。
  • S100B特异性为88.5%(95%CI 85.2%-91.3%),不能据此安全排除颅内出血。
  • 结论不支持用血浆S100B水平替代或减少mTBI患者的头部CT检查。

适用人群与场景

  • 纳入:加拿大5家急诊科、非住院的轻度创伤性脑损伤患者,GCS 13-15分,伤后24小时内采集血样。
  • 排除:原文未提及具体排除标准。
  • 场景:急诊科,非住院患者。

诊断标准与关键阈值

  • mTBI定义:GCS 13-15分(原文仅给出GCS范围,未给出其他诊断标准)。
  • 临床显著脑损伤:原文未给出具体判定标准或界值。
  • S100B检测:ELISA法,原文未给出阳性阈值。

处置流程与药物剂量

  • 原文未提及基于S100B的处置流程或药物剂量。

红旗征与不能漏的情况

  • 原文未提及红旗征或需要立刻处理的情况。

研究设计与关键结果

  • 研究类型:前瞻性多中心队列研究的二次分析,5家加拿大急诊科,2013-2016年。
  • 样本量:476例非住院mTBI患者,平均年龄41±18岁,女性150例(31.5%)。
  • 主要终点:临床显著颅内出血24例(5.0%);非临床显著脑损伤13例(2.7%);总脑损伤37例(7.8%)。
  • S100B中位值(Q1-Q3):临床显著脑损伤组0.043 µg/L(0.008-0.080),无临床显著脑损伤组0.039 µg/L(0.023-0.059)。
  • S100B单独检测临床显著脑损伤的敏感性16.7%(95%CI 4.7%-37.4%),特异性88.5%(95%CI 85.2%-91.3%)。
  • 结论:S100B水平与mTBI临床显著颅内病变无关。

证据类型、等级与局限

  • 证据类型:前瞻性多中心队列研究的二次分析(亚组分析)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:二次分析;样本量476例,临床显著颅内出血事件仅24例;单次S100B检测;原文未报告盲法细节(除CT由对生物标志物不知情的放射科医师审阅外);未给出S100B阳性阈值。

对床旁实践的改变

  • 不改变现有实践:本研究不支持用血浆S100B水平替代或减少mTBI患者的头部CT检查。
  • 适用人群:急诊科非住院、GCS 13-15分的mTBI患者。
  • 常见陷阱:S100B敏感性极低(16.7%),不能依据S100B阴性结果安全排除临床显著颅内出血。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Clinical assessment of patients with mild traumatic brain injury (mTBI) is challenging and overuse of head CT in the ED is a major problem. Several studies have attempted to reduce unnecessary head CTs following a mTBI by identifying new tools aiming to predict intracranial bleeding. Higher levels of S100B protein have been associated with intracranial haemorrhage following a mTBI in previous literature. The main objective of this study is to assess whether plasma S100B protein level is associated with clinically significant brain injury and could be used to reduce the number of head CT post-mTBI.

METHODS: Study design: secondary analysis of a prospective multicentre cohort study conducted between 2013 and 2016 in five Canadian EDs. Inclusion criteria: non-hospitalised patients with mTBI with a GCS score of 13-15 in the ED and a blood sample drawn within 24 hours after the injury. Data collected: sociodemographic and clinical data were collected in the ED. S100B protein was analysed using ELISA. All CT scans were reviewed by a radiologist blinded to the biomarker results. Main outcome: the presence of clinically important brain injury.

RESULTS: 476 patients were included. Mean age was 41±18 years old and 150 (31.5%) were women. Twenty-four (5.0%) patients had a clinically significant intracranial haemorrhage. Thirteen patients (2.7%) presented a non-clinically significant brain injury. A total of 37 (7.8%) brain injured patients were included in our study. S100B median value (Q1-Q3) was: 0.043 µg/L (0.008-0.080) for patients with clinically important brain injury versus 0.039 µg/L (0.023-0.059) for patients without clinically important brain injury. Sensitivity and specificity of the S100B protein level, if used alone to detect clinically important brain injury, were 16.7% (95% CI 4.7% to 37.4%) and 88.5% (95% CI 85.2% to 91.3%), respectively.

CONCLUSION: Plasma S100B protein level was not associated with clinically significant intracranial lesion in patients with mTBI.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Blais Lécuyer J, Mercier É, Tardif PA, et al. S100B protein level for the detection of clinically significant intracranial haemorrhage in patients with mild traumatic brain injury: a subanalysis of a prospective cohort study. Emerg Med J. 2020. PMID: 33355233. doi:10.1136/emermed-2020-209583

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。